News

The funding comprises $750,000 from the Muscular Dystrophy Association (MDA), $250,000 from Parent Project Muscular Dystrophy (PPMD) and $500,000 from a group of four independent Duchenne foundations spanning

Under future technical and commercial agreements, Angel will utilize its GMP facility at Cramlington to expedite and optimize the expression systems provided by TransGenRx. TransGenRx chief scientific officer

Sygnature and Cyprotex will extend their collaborative sales and marketing initiative to provide discovery chemistry/ADME-Tox/DMPK service to accelerate their clients’ drug discovery projects into development. Cyprotex CEO Anthony

The Phase I study of GLPG0778 is a part of an immuno-inflammatory alliance with GSK, and involved 45 healthy volunteers, who were divided into 5 cohorts, receiving in

The company intends to manufacture total of 480 million doses of the vaccine, which is in line with its commitment made in March 2010 to supply up to

The production of SSC is said to make use of the company’s proprietary biotechnology which will reduce energy consumption by 66%, produce 90% less waste and have 50%

The third tranche included $21.4m in equity financing from Radius’ current investors, bringing gross proceeds received to date from the $91m financing to $78.7m. The company intends to

The trial has recruited patients from 36 centers across Europe. This double blind trial is comparing two doses of TB-402 (25mg and 50mg), given as a single intravenous

Both the studies showed that the investigational drug candidate was statistically superior to placebo for all primary and secondary endpoints. Efinaconazole was also found to be generally safe